✦ LIBER ✦

A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma

✍ Scribed by Bitting, Rhonda L.; Healy, Patrick; Creel, Patricia A.; Turnbull, James; Morris, Karla; Wood, Sarah Yenser; Hurwitz, Herbert I.; Starr, Mark D.; Nixon, Andrew B.; Armstrong, Andrew J.; George, Daniel J.

Book ID: 122319113
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 912 KB
Volume: 12
Category: Article
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2013.11.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase Ib study of tivozanib (AV-951) in

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma

✍ Fishman, M.N.; Srinivas, S.; Hauke, R.J.; Amato, R.J.; Esteves, B.; Cotreau, M.M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 470 KB

359 Phase Ib and pharmacokinetic studies

359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors

✍ M. Campone; V. Levy; V. Delecroix; E. Bourbouloux; D. Bootle; C. Tanaka; N. Shan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 144 KB

A phase II study of vinblastine in combi

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

✍ Jordan Berlin; A. Christie King; Kendra Tutsch; John W. Findlay; Peter Kohler; M 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 447 KB

Phase I Study Combining Treatment with T

Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

✍ Premal H. Patel; Peggy L. Senico; Rafael E. Curiel; Robert J. Motzer 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 279 KB

A Phase II study of irinotecan in patien

A Phase II study of irinotecan in patients with advanced renal cell carcinoma

✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

A phase II study of pyrazoloacridine in

A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma

✍ William J. Berg; John McCaffrey; Lawrence H. Schwartz; Tania Mariani; Madhu Mazu 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 44 KB